Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shai Efrati has a total of 241 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hyperbaric oxygen in cancer patients: a review of clinical safety, tissue selectivity, and therapeutic synergy

    by Avishai Abrahami, Shai Efrati

    Background: For decades, the clinical application of Hyperbaric Oxygen Therapy (HBOT) in oncology has been constrained by theoretical concerns that hyperoxia might act as an unintended proliferative accelerator or tumor “fertilizer” by encouraging angiogenesis. This comprehensive review synthesizes the historical context, systematic review data, mechanistic literature, and clinical evidence to resolve three distinct questions: whether HBOT is safe in cancer patients, why its physiological effects diverge between healthy and malignant tissues, and how it can be leveraged synergistically with standard and novel oncological modalities. Safety Findings: The human clinical record demonstrates a consistent, reproducible record of clinical safety across published cohorts. More than 38 independent human clinical reports published since 1970 have examined HBOT in cancer patients, and all found no association with tumor growth, recurrence, or metastasis. This consistency is reinforced by 19 randomized trials comprising 1,103 tumor-bearing patients prospectively evaluated under hyperoxia, none of which showed malignant acceleration at any site. A mathematical power analysis applied to this clinical corpus demonstrates that the probability of a genuine, undetected oncological hazard is less than 1 × 10 − 11 . Tissue Selectivity and Mechanisms: This safety profile rests on fundamental tissue selectivity. While intermittent hyperoxia drives tissue regeneration and upregulates antioxidant defenses in healthy host cells, malignant cells operating under the Warburg phenotype—characterized by severe mitochondrial structural degradation and cristolysis—possess a compressed redox margin. By reversing microenvironmental tumor hypoxia, hyperbaric oxygen destabilizes HIF-1alpha, suppresses glycolytic enzyme machinery, induces intrinsic mitochondrial apoptosis, and reverses epithelial-to-mesenchymal transition. Therapeutic Synergy: Beyond clinical safety, hyperbaric hyperoxia acts as a potent therapeutic sensitizer. In randomized trials, adding HBOT to radiotherapy significantly reduced mortality and local recurrence in head and neck cancers. Mechanistically, HBOT dismantles dense extracellular matrix barriers, rebalances immunosuppressive myeloid components, and enhances T-cell infiltration, providing a clear rationale for combination with immunotherapies, chemotherapies, and ketogenic metabolic therapy. Conclusion: Active or historical malignancy is not a valid contraindication for hyperbaric oxygen intervention. Hyperbaric oxygen functions as a tissue-selective biological signal—safe in healthy host tissue, disruptive to malignant survival architecture, and synergistic with modern oncological therapeutics.

  • Open Access

    Hyperbaric oxygen therapy improves post-concussion symptoms in adults with childhood traumatic brain injury: a retrospective cohort study

    by Adi Shabi Shlifer, Gil Suzin, Ran Shorer, Erez Lang, Shachar Finci, Karin Elman-Shina, Keren Doenyas-Barak, Shai Efrati

    Post-concussion syndrome (PCS) following childhood traumatic brain injury (TBI) can result in persistent cognitive impairments that extend into adulthood, yet it remains significantly underdiagnosed and undertreated. This study evaluated the effects of hyperbaric oxygen therapy (HBOT) on chronic neurocognitive symptoms in adults with PCS stemming from pediatric TBI. We conducted a retrospective analysis of patients treated with HBOT at the “Sagol Center for Hyperbaric Medicine and Research” between 2017 and 2024. Inclusion criteria included TBI before age 17, HBOT initiation after age 20, and the availability of computerized cognitive assessments before and after treatment. All participants received at least 40 sessions of HBOT, consisting of 90 min of 100% oxygen at 2 ATA with air breaks. Twenty-six adults (mean age 31.7 ± 8.6 years) who sustained TBI in childhood (mean age at injury 7.7 ± 5.8 years) met inclusion criteria. Following HBOT, statistically significant improvements were observed in all cognitive domains except for motor skills (global cognition, memory, executive function, attention and information processing speed; all adjusted p < 0.05; effect sizes r = 0.62–0.78, Wilcoxon signed-rank test). These improvements were independent of time since injury (mean 23.6 ± 9.3 years) and initial TBI severity. Notably, individuals with a history of mild TBI exhibited similar impairments and treatment response to those with more severe injuries. These findings suggest that HBOT may induce meaningful neurocognitive improvement even decades after pediatric TBI, supporting its potential role in long-term rehabilitation strategies for this underserved population.


  • Open Access

    Hyperbaric Oxygen Therapy for PTSD: Threshold Effect for Sustained Symptom Improvement in a Biologically Based Treatment

    by Dor Danan, Yaniv Grosskopf, Avi Mayo, Shai Efrati, Ilan Kutz, Erez Lang, Uri Alon, Keren Doenyas‐Barak

    Objective: Emerging evidence suggests that hyperbaric oxygen therapy (HBOT) promotes neuroplasticity and alleviates symptoms in individuals with post‐traumatic stress disorder (PTSD). As a biologically based treatment, HBOT may demonstrate a threshold effect, wherein sufficient treatment leads to sustained symptom improvement, while insufficient treatment results in diminishing benefits. This study tested the threshold hypothesis reanalyzing the end of treatment and a 3‐month follow‐up symptoms scores of a randomized controlled trial (RCT) comparing HBOT to sham treatment in 56 male veterans with treatment‐resistant PTSD.Methods: A post hoc analysis was conducted on data from the RCT. The elbow method identifies thresholds in the relationship between end‐of‐treatment improvement and follow‐up outcomes. Spearman's rank correlation was used to assess the relationship between changes in cluster‐specific symptoms and total CAPS scores at the end of treatment and at follow‐up evaluation.Results: Participants achieving ≥ 35% improvement by the end of treatment demonstrated continued improvement at follow‐up (p = 2e−6). Significant correlations were observed between changes in each of the symptom clusters and total CAPS scores, with the strongest correlation in intrusive symptoms (Cluster B, r = 0.74, p = 10e−4 and r = 0.80, p = 10e−4). Changes in avoidance (Cluster C, r = 0.70, p = 10e−4) at the end of treatment were the best predictors of follow‐up improvements.Conclusions: A threshold effect is evident in HBOT treatment for PTSD, where ≥ 35% improvement posttreatment predicts continued gains. Symptom reduction beyond the threshold may serve as a target for HBOT when prescribed for PTSD. The suggested underlying physiological mechanisms, involving bistable circuit dynamics, justify evaluating potential threshold effect in other treatment modalities.Trial Registration: ClinicalTrial.gov identifier: NCT04518007


  • Nutritional and Inflammatory Aspects of Low Parathyroid Hormone in Maintenance Hemodialysis Patients—A Longitudinal Study

    by Shani Zilberman-Itskovich, Baker Algamal, Ada Azar, Shai Efrati, Ilia Beberashvili


  • Open Access

    Hyperbaric oxygen therapy vs. pharmacological intervention in adults with fibromyalgia related to childhood sexual abuse: prospective, randomized clinical trial

    by Rahav Boussi-Gross, Merav Catalogna, Erez Lang, Zipora Shamai, Jacob N. Ablin, Valerie Aloush, Keren Doenyas-Barak, Mordechai Lorberboym, Rachel Lev-Wiesel, Shai Efrati

    Fibromyalgia syndrome (FMS) is a chronic pain syndrome characterized by disruptions in pain processing within the central nervous system. It exhibits a high prevalence among patients with a history of traumatic experiences, notably childhood sexual abuse (CSA). This study compared the efficacy of hyperbaric oxygen therapy (HBOT) to the current pharmacological standard of care for individuals suffering from CSA-related FMS. Forty-eight participants diagnosed with FMS and a history of CSA were randomly assigned to either the HBOT group (60 sessions of 100% oxygen at 2 ATA for 90 min, with air breaks every 5 min) or the medication (MED) group (FDA-approved medications, Pregabalin and Duloxetine). The primary endpoint was the Fibromyalgia impact questionnaire (FIQ) score, while secondary endpoints encompassed emotional status and daily functioning questionnaires, as well as pain thresholds and conditioned pain modulation tests. Brain activity was evaluated through single photon emission computed tomography (SPECT). Results revealed a significant group-by-time interaction for the FIQ score favoring HBOT over MED (p < 0.001), with a large effect size (Cohen's d = − 1.27). Similar findings were observed in emotional symptoms and functional measures. SPECT imaging demonstrated an increase in activity in pre-frontal and temporal brain areas, which correlated with symptoms improvement. In conclusion, HBOT exhibited superior benefits over medications in terms of physical, functional, and emotional improvements among FMS patients with a history of CSA. This associated with increased activity in pre-frontal and temporal brain areas, highlighting the neuroplasticity effect of HBOT.


  • Open Access

    Functional MRI evaluation of hyperbaric oxygen therapy effect on hand motor recovery in a chronic post-stroke patient: a case report and physiological discussion

    by Merav Catalogna, Amir Hadanny, Yoav Parag, Moran Adler, Vicktoria Elkarif, Shai Efrati

    Introduction: Impairments in activities of daily living (ADL) are a major concern in post-stroke rehabilitation. Upper-limb motor impairments, specifically, have been correlated with low quality of life. In the current case report, we used both task-based and resting state functional MRI (fMRI) tools to investigate the neural response mechanisms and functional reorganization underlying hyperbaric oxygen therapy (HBOT)-induced motor rehabilitation in a chronic post-stroke patient suffering from severe upper-limb motor impairment.Methods: We studied motor task fMRI activation and resting-state functional connectivity (rsFC) in a 61-year-old right-handed male patient who suffered hemiparesis and physical weakness in the right upper limb, 2 years after his acute insult, pre- and post-treatment of 60 daily HBOT sessions. Motor functions were assessed at baseline and at the end of the treatment using the Fugl–Meyer assessment (FMA) and the handgrip maximum voluntary contraction (MVC).Results: Following HBOT, the FMA score improved from 17 (severe impairment) to 31 (moderate impairment). Following the intervention during trials involving the affected hand, there was an observed increase in fMRI activation in both the supplementary motor cortex (SMA) and the premotor cortex (PMA) bilaterally. The lateralization index (LI) decreased from 1 to 0.63, demonstrating the recruitment of the contralesional hemisphere. The region of interest, ROI-to-ROI, analysis revealed increased post-intervention inter-hemispheric connectivity (P = 0.002) and a between-network connectivity increase (z-score: 0.35 ± 0.21 to 0.41 ± 0.21, P < 0.0001). Seed-to-voxel-based rsFC analysis using the right SMA as seed showed increased connectivity to the left posterior parietal cortex, the left primary somatosensory cortex, and the premotor cortex.Conclusion: This study provides additional insights into HBOT-induced brain plasticity and functional improvement in chronic post-stroke patients.


  • Open Access

    Hyperbaric oxygen therapy compared to pharmacological intervention in fibromyalgia patients following traumatic brain injury: A randomized, controlled trial

    by Jacob N Ablin, Erez Lang, Merav Catalogna, Valerie Aloush, Amir Hadanny, Keren Doenyas-Barak, Shachar Finci, Nir Polak, Gregory Fishlev, Calanit Korin, et al.

    Fibromyalgia is a chronic pain syndrome with unsatisfactory response to current treatments. Physical trauma, including traumatic brain Injury (TBI) is among the etiological triggers. Hyperbaric Oxygen therapy (HBOT) is an intervention that combines 100% oxygen with elevated atmospheric pressure. HBOT has been applied as a neuro-modulatory treatment in central nervous system–related conditions. The current study investigated the utility of HBOT for TBI–related fibromyalgia. Fibromyalgia patients with a history of TBI were randomized to either HBOT or pharmacological intervention. HBOT protocol comprised 60 daily sessions, breathing 100% oxygen by mask at 2 absolute atmospheres (ATA) for 90 minutes. Pharmacological treatment included Pregabalin or Duloxetine. The primary outcome was subjective pain intensity on visual analogue scale (VAS); Secondary endpoints included questionnaires assessing fibromyalgia symptoms as well as Tc-99m-ECD SPECT brain imaging. Pain threshold and conditioned pain modulation (CPM) were also assessed. Results demonstrated a significant group-by-time interaction in pain intensity post-HBOT compared to the medication group (p = 0.001), with a large net effect size (d = -0.95) in pain intensity reduction following HBOT compared to medications. Fibromyalgia related symptoms and pain questionnaires demonstrated significant improvements induced by HBOT as well as improvements in quality of life and increase in pain thresholds and CPM. SPECT demonstrated significant group-by-time interactions between HBOT and medication groups in the left frontal and the right temporal cortex. In conclusion, HBOT can improve pain symptoms, quality of life, emotional and social function of patients suffering from FMS triggered by TBI. The beneficial clinical effect is correlated with increased brain activity in frontal and parietal regions, associated with executive function and emotional processing.


  • Open Access

    Effects of hyperbaric oxygen therapy on functional and structural connectivity in post-COVID-19 condition patients: A randomized, sham-controlled trial

    by Merav Catalogna, Efrat Sasson, Amir Hadanny, Yoav Parag, Shani Zilberman-Itskovich, Shai Efrati


  • Open Access

    Hyperbaric Oxygen Therapy Alleviates Social Behavior Dysfunction and Neuroinflammation in a Mouse Model for Autism Spectrum Disorders

    by Inbar Fischer, Sophie Shohat, Gilad Levy, Ela Bar, Sari Schokoroy Trangle, Shai Efrati, Boaz Barak

    Autism spectrum disorder (ASD) is a multifactorial neurodevelopmental disorder (NDD) characterized by impaired social communication and repetitive behavior, among other symptoms. ASD is highly heritable, with SHANK3 being one of the high-risk genes for ASD. In recent years, knowledge has been growing regarding the neuroplasticity effect induced by hyperbaric oxygen therapy (HBOT) and its potential use for ASD. Here, we characterized the effect of HBOT on a mouse model for ASD with the human genetic condition of InsG3680 mutation in the Shank3 gene. As compared to placebo, HBOT improved social behavior and reduced neuroinflammation in the cortex of the InsG3680(+/+) mice. Specifically, HBOT induced upregulation of Insulin-like growth factor 1 (Igf1) expression levels and reduced the number of Iba1-positive cells in the mouse model for ASD compared to placebo control. Together, our research suggests that HBOT has the potential to improve the clinical outcome of ASD by ameliorating some of the core pathophysiological processes responsible for the development of the disorder.


  • Top Cited Papers
    Open Access

    Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial

    by Shani Zilberman-Itskovich, Merav Catalogna, Efrat Sasson, Karin Elman-Shina, Amir Hadanny, Erez Lang, Shachar Finci, Nir Polak, Gregory Fishlev, Calanit Korin, et al.

    Post-COVID-19 condition refers to a range of persisting physical, neurocognitive, and neuropsychological symptoms after SARS-CoV-2 infection. The mechanism can be related to brain tissue pathology caused by virus invasion or indirectly by neuroinflammation and hypercoagulability. This randomized, sham-control, double blind trial evaluated the effect of hyperbaric oxygen therapy (HBOT or HBO2 therapy) on post-COVID-19 patients with ongoing symptoms for at least 3 months after confirmed infection. Seventy-three patients were randomized to receive daily 40 session of HBOT (n = 37) or sham (n = 36). Follow-up assessments were performed at baseline and 1–3 weeks after the last treatment session. Following HBOT, there was a significant group-by-time interaction in global cognitive function, attention and executive function (d = 0.495, p = 0.038; d = 0.477, p = 0.04 and d = 0.463, p = 0.05 respectively). Significant improvement was also demonstrated in the energy domain (d = 0.522, p = 0.029), sleep (d = − 0.48, p = 0.042), psychiatric symptoms (d = 0.636, p = 0.008), and pain interference (d = 0.737, p = 0.001). Clinical outcomes were associated with significant improvement in brain MRI perfusion and microstructural changes in the supramarginal gyrus, left supplementary motor area, right insula, left frontal precentral gyrus, right middle frontal gyrus, and superior corona radiate. These results indicate that HBOT can induce neuroplasticity and improve cognitive, psychiatric, fatigue, sleep and pain symptoms of patients suffering from post-COVID-19 condition. HBOT’s beneficial effect may be attributed to increased brain perfusion and neuroplasticity in regions associated with cognitive and emotional roles.